Don't Use Remdesivir in Hospitalized COVID-19 Patients, WHO Panel Warns
Click the image below to enlarge the infographic.
- The World Health Organization (WHO) has warned against using Gilead's Remesivir in patients hospitalized with COVID-19, after the agency's multicounty Solidarity Trial showed the drug had "little or no effect" on COVID-19 survival
- The agency's Guideline Development Group (GDP) issued the guidance Friday and said there was no evidence of improved outcomes in patients who used the drug
- The antiviral drug was first approved by the FDA to treat coronavirus after a phase 3 trial showed that it was associated with faster recovery rates in adults with mild to severe COVID-19 cases
- The FDA then approved it for use in adult and pediatric patients 12 years and older weighing 88 pounds or greater for hospital treatment of COVID-19
- The WHO'S Solidarity Trial showed that the drug had little or no effect on 28-day mortality or length of hospital stay for coronavirus patients